RxDoctor Payments Data

Hussein Rahim, MD

Cardiovascular Disease · New York, NYNPI 1053654277

Payments from drug & device makers

$50,109in general payments, 2019–2025

Across 209 payments — averaging $239.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Boston Scientific$15K
  • Edwards Lifesciences$4K
  • Abbott$4K
  • Abiomed$2K
  • Novartis$388
  • plus $934 from 13 others
$2,642in research payments, 2019–2025

Across 2 payments — averaging $1320.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K
  • Abiomed$342

What the payments were for

  • Grants$36,00072%
  • Travel & lodging$6,32413%
  • Food & beverage$7,70315%
  • Education$820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,109 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$243,739
Medicare patients
426
Services billed
1,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$34,770
BrilintaTicagrelor29$30,543
EntrestoSacubitril/Valsartan23$22,760
Metoprolol Succinate57$854
ClopidogrelClopidogrel Bisulfate57$836
Atorvastatin Calcium52$726
Rosuvastatin Calcium30$582
Isosorbide Mononitrate ErIsosorbide Mononitrate34$397
Ezetimibe12$389
Losartan Potassium30$285
Pantoprazole Sodium11$249
Carvedilol25$236
Amlodipine Besylate45$195
Spironolactone14$168
Metoprolol Tartrate14$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$34,77032 claims
AstraZenecaBrilinta$25$30,54329 claims
NovartisEntresto$388$22,76023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →